Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Xiaofeng Xu, Yuhua Yan, Qingying Xun, Jiayu Shi, Xiangyi Kong, Jun Wu & Huaijun Zhou. (2019) Combined silencing of VEGF-A and angiopoietin-2, a more effective way to inhibit the Ishikawa endometrial cancer cell line. OncoTargets and Therapy 12, pages 1215-1223.
Read now
Read now
Alice Bergamini, Umberto Leone Roberti Maggiore, Simone Ferrero, Emanuela Rabaiotti, Riccardo Viganò, Micaela Petrone, Patrizia De Marzi, Stefano Salvatore, Massimo Candiani & Giorgia Mangili. (2015) Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. Expert Opinion on Investigational Drugs 24:3, pages 345-362.
Read now
Read now
Articles from other publishers (10)
Yunhai Chuai, Ivana Rizzuto, Xia Zhang, Ying Li, Guanghai Dai, Sophie J Otter, Rasiah Bharathan, Alexandra Stewart & Aiming Wang. (2021) Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. Cochrane Database of Systematic Reviews 2021:3.
Crossref
Crossref
Lian He, Huijun Yang, Fei Liu, Yiyan Chen, Sijia Tang, Wei Ji, Jianli Tang, Zhudong Liu, Yunjun Sun, Shengbiao Hu, Youming Zhang, Xiong Liu, Weitao Huang, Xuezhi Ding & Liqiu Xia. (2017)
Escherichia coli
Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth
. Oncotarget 8:49, pages 85772-85782.
Crossref
Crossref
Krishnansu S Tewari, Michael W Sill, Richard T Penson, Helen Huang, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J Reid, Mario M Leitao, Helen E Michael, Philip J DiSaia, Larry J Copeland, William T Creasman, Frederick B Stehman, Mark F Brady, Robert A Burger, J Tate Thigpen, Michael J Birrer, Steven E Waggoner, David H Moore, Katherine Y Look, Wui-Jin Koh & Bradley J Monk. (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). The Lancet 390:10103, pages 1654-1663.
Crossref
Crossref
Sonam Sinha, Sajid Khan, Samriddhi Shukla, Amar Deep Lakra, Sudhir Kumar, Gunjan Das, Rakesh Maurya & Syed Musthapa Meeran. (2016) Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK/MMP-9 signaling axis. The International Journal of Biochemistry & Cell Biology 77, pages 41-56.
Crossref
Crossref
Annarita Miluzio, Stefania Oliveto, Elisa Pesce, Luciano Mutti, Bruno Murer, Stefano Grosso, Sara Ricciardi, Daniela Brina & Stefano Biffo. (2015)
Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth
in vivo
. Oncotarget 6:35, pages 37471-37485.
Crossref
Crossref
Yasuto Kinose, Kenjiro Sawada, Hiroshi Makino, Tomonori Ogura, Tomoko Mizuno, Noriko Suzuki, Tomoyuki Fujikawa, Eiichi Morii, Koji Nakamura, Ikuko Sawada, Aska Toda, Kae Hashimoto, Aki Isobe, Seiji Mabuchi, Tsuyoshi Ohta, Akiko Itai, Ken-ichirou Morishige, Hirohisa Kurachi & Tadashi Kimura. (2015) IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment. Molecular Cancer Therapeutics 14:4, pages 909-919.
Crossref
Crossref
Oana Mihaela Tudoran, Olga Soritau, Loredana Balacescu, Laura Pop, Guillaume Meurice, Simona Visan, Staffan Lindberg, Alexandru Eniu, Ulo Langel, Ovidiu Balacescu & Ioana Berindan-Neagoe. (2015) PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation. Journal of Cellular and Molecular Medicine 19:2, pages 371-382.
Crossref
Crossref
Dong Hoon Suh, Hee Seung Kim, Boyun Kim & Yong Sang Song. (2014) Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication. Biochemical Pharmacology 92:1, pages 43-54.
Crossref
Crossref
Junya Kuroyanagi, Yasuhito Shimada, Beibei Zhang, Michiko Ariyoshi, Noriko Umemoto, Yuhei Nishimura & Toshio Tanaka. (2014) Zinc finger MYND‐type containing 8 promotes tumour angiogenesis via induction of vascular endothelial growth factor‐A expression. FEBS Letters 588:18, pages 3409-3416.
Crossref
Crossref
Jonathan D Black, Diana P English, Dana M Roque & Alessandro D Santin. (2014) Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer. Women's Health 10:1, pages 45-57.
Crossref
Crossref